Filana Therapeutics (FLNA) Net Income (2010 - 2026)

Filana Therapeutics has reported Net Income for 17 years, with the latest figure at -$8.8 million in Q2 2026.

• On a quarterly basis, Net Income rose 80.13% year-over-year to -$8.8 million in Q2 2026; TTM through Jun 2026 was -$23.9 million, a 80.7% increase from a year earlier, with the FY2025 full-year figure at -$203.0 million, up 12.13% from the prior year.
• Net Income was -$8.8 million for Q2 2026 at Filana Therapeutics, up from -$10.6 million in the prior quarter.
• The five-year high for Net Income was $6.4 million in Q4 2025, with the low at -$98.9 million in Q4 2023.
• Average Net Income over 5 years is -$29.7 million, with a median of -$24.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Net Income sank 413.33% in 2022, then jumped 122.97% in 2025.
• Over 5 years, Net Income stood at -$73.8 million in 2022, then sank by 33.92% to -$98.9 million in 2023, then jumped by 71.84% to -$27.8 million in 2024, then soared by 122.97% to $6.4 million in 2025, then tumbled by 237.79% to -$8.8 million in 2026.
• The last three Net Income figures came in at -$8.8 million (Q2 2026), -$10.6 million (Q1 2026), and $6.4 million (Q4 2025), per Business Quant data.